Parliamentary Standing Committee has recommended reviewing India's medicine pricing policy after finding that only 18% of the pharmaceutical market is under direct government price control. It said manufacturers determine prices for the remaining 82% of medicines and called for measures to prevent arbitrary initial pricing while keeping medicines affordable.